Interaction Checker

Sunitinib : interactions médicamenteuses

Sunitinib (Sutent) présente 271 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 3 de niveau majeur, 267 de niveau modéré, 1 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (3)

  • BévacizumabMajeure

    Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of SUTENT as monotherapy and administered in combination with bevacizumab. (notice Sunitinib, Mises en garde et précautions)

  • Itraconazoleantifongique azoléMajeure

    Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-­emtansine Vinca alkaloids Not recommended during and 2 weeks after TOLSURA treatment. (notice Itraconazole, Interactions médicamenteuses)

  • Voriconazoleantifongique azoléMajeure

    Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of voriconazole. (notice Voriconazole, Interactions médicamenteuses)

Interactions modérées (267)

  • AcarboseantidiabétiqueModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • AcébutololbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Acide alendroniquebisphosphonateModérée

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (notice Sunitinib, Mises en garde et précautions)

  • Acide étacryniquediurétique de l'anseModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Acide ibandroniquebisphosphonateModérée

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (notice Sunitinib, Mises en garde et précautions)

  • Acide pamidroniquebisphosphonateModérée

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (notice Sunitinib, Mises en garde et précautions)

  • Acide risédroniquebisphosphonateModérée

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (notice Sunitinib, Mises en garde et précautions)

  • Acide zolédroniquebisphosphonateModérée

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (notice Sunitinib, Mises en garde et précautions)

  • AdénosineantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • AlfuzosinealphabloquantModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • AliskirèneantihypertenseurModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Alogliptineinhibiteur de la DPP-4Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Alogliptine et metformineinhibiteur de la DPP-4Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Amiloridediurétique épargneur de potassiumModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • AmiodaroneantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • Amitriptylineantidépresseur tricycliqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Amlodipineinhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Amlodipine et atorvastatineinhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Amlodipine et bénazéprilinhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Amlodipine et olmésartaninhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Amlodipine et valsartaninhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Anagrélidemédicament allongeant l'intervalle QTModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Aprépitantinhibiteur du CYP3A4Modérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Armodafinilstimulant du SNCModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • AsénapineantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • AtazanavirantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • AténololbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Aténolol et chlortalidonebêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Azilsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Azithromycineantibiotique macrolideModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Bénazéprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • BétaxololbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Bexagliflozineinhibiteur du SGLT2Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • BisoprololbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Bisoprolol et hydrochlorothiazidebêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Bosentaninducteur du CYP3A4Modérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Canagliflozineinhibiteur du SGLT2Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Candésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Captoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • CarbamazépineanticonvulsivantModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • CarvédilolbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • CénobamateanticonvulsivantModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • ChloroquineantipaludiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Chlorothiazidediurétique thiazidiqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • ChlorpromazineantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Chlortalidonediurétique thiazidiqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • CiclosporineimmunosuppresseurModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Cimétidineantihistaminique H2Modérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • CiprofloxacinefluoroquinoloneModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • CitalopramISRSModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Clarithromycineantibiotique macrolideModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • ClobazambenzodiazépineModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Clonidineagoniste alpha-adrénergiqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • ClozapineantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Dapagliflozineinhibiteur du SGLT2Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Dapagliflozine et metformineinhibiteur du SGLT2Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • DarunavirantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Darunavir et cobicistatantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Déférasiroxsupplément de ferModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Deutétrabénazineinhibiteur de VMAT2Modérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • DexaméthasonecorticoïdeModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Dextrométhorphane et quinidinemédicament sérotoninergiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Digoxineglycoside digitaliqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • Diltiazeminhibiteur calciqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Dinitrate d'isosorbide et hydralazinedérivé nitréModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • DisopyramideantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • DofétilideantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • DoxazosinealphabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • DronédaroneantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • Dropéridolantagoniste de la dopamineModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Dulaglutideagoniste du récepteur du GLP-1Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • ÉfavirenzantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Éfavirenz, lamivudine et ténofovirantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Elvitégravir, cobicistat, emtricitabine et ténofovirantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Empagliflozineinhibiteur du SGLT2Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Empagliflozine et metformineinhibiteur du SGLT2Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Énalaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Énalaprilateinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Éplérénoneantagoniste de l'aldostéroneModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Érythromycineantibiotique macrolideModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • EscitalopramISRSModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • EslicarbazépineanticonvulsivantModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • EsmololbêtabloquantModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • ÉtravirineantirétroviralModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • ÉvérolimusimmunosuppresseurModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Exénatideagoniste du récepteur du GLP-1Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Félodipineinhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • FingolimodimmunosuppresseurModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • FlécaïnideantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • Fluconazoleantifongique azoléModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • FluoxétineISRSModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • FosamprénavirantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Fosaprépitantinhibiteur du CYP3A4Modérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Fosinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • FosphénytoïneanticonvulsivantModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Furosémidediurétique de l'anseModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Glibenclamidesulfamide hypoglycémiantModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Glibenclamide et metforminesulfamide hypoglycémiantModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Glimépiridesulfamide hypoglycémiantModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Glipizidesulfamide hypoglycémiantModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Glipizide et metforminesulfamide hypoglycémiantModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Granisétronmédicament allongeant l'intervalle QTModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • GriséofulvineantifongiqueModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Guanfacineagoniste alpha-adrénergiqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • HalopéridolantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • HydralazinevasodilatateurModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Hydrochlorothiazidediurétique thiazidiqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Hydroxychloroquinemédicament allongeant l'intervalle QTModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • HydroxyzineantihistaminiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • IbutilideantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • IlopéridoneantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Imatinibinhibiteur du CYP3A4Modérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Indapamidediurétique thiazidiqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Insuline asparteinsulineModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Insuline dégludecinsulineModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Insuline détémirinsulineModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Insuline glargineinsulineModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Insuline lisproinsulineModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Insuline rapide (humaine)insulineModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Irbésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • IsoniazideantibiotiqueModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Isradipineinhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Ivacaftorinhibiteur du CYP3A4Modérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Kétoconazoleantifongique azoléModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • LabétalolbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • LénacapavirantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • LévofloxacinefluoroquinoloneModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Lévothyroxinehormone thyroïdienneModérée

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (notice Sunitinib, Mises en garde et précautions)

  • Lévothyroxine et liothyroninehormone thyroïdienneModérée

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (notice Sunitinib, Mises en garde et précautions)

  • Lidocaïneanesthésique localModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • Lidocaïne et prilocaïneanesthésique localModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • Linagliptineinhibiteur de la DPP-4Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Linagliptine et metformineinhibiteur de la DPP-4Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Liothyroninehormone thyroïdienneModérée

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (notice Sunitinib, Mises en garde et précautions)

  • Liraglutideagoniste du récepteur du GLP-1Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Lisinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Lofexidineagoniste alpha-adrénergiqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Lopéramidemédicament allongeant l'intervalle QTModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Lopinavir et ritonavirantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Lorlatinibinducteur du CYP3A4Modérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Losartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • MécamylamineantihypertenseurModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • MetforminebiguanideModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • MéthadoneopioïdeModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • MéthyldopaantihypertenseurModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Métolazonediurétique thiazidiqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • MétoprololbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Métoprolol et hydrochlorothiazidebêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • MexilétineantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • Mifépristoneinhibiteur du CYP3A4Modérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • MiglitolantidiabétiqueModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • MinoxidilvasodilatateurModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Mirabégronagoniste bêta-adrénergiqueModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Mitapivatinducteur du CYP3A4Modérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Mitotaneinducteur du CYP3A4Modérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Modafinilstimulant du SNCModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Moexiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • MoxifloxacinefluoroquinoloneModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • NadololbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Nafcillineantibiotique de la famille des pénicillinesModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • NatéglinideglinideModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • NébivololbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • NéfazodoneantidépresseurModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • NévirapineantirétroviralModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Nicardipineinhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Nifédipineinhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Nilotinibmédicament allongeant l'intervalle QTModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Nirmatrelvir et ritonavirantiviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Nisoldipineinhibiteur calcique dihydropyridiniqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Nitroprussiate de sodiumvasodilatateurModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • OfloxacinefluoroquinoloneModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Olanzapine et fluoxétineantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Olmésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Ondansétronmédicament allongeant l'intervalle QTModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • OxcarbazépineanticonvulsivantModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Palbociclibinhibiteur du CYP3A4Modérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • PalipéridoneantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Pentamidinemédicament allongeant l'intervalle QTModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • PérampanelanticonvulsivantModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Périndoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • PhénobarbitalbarbituriqueModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • PhénoxybenzaminealphabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Phentermine et topiramatestimulant du SNCModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • PhénytoïneanticonvulsivantModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • PimavansérineantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • PimozideantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • PindololbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • PioglitazonethiazolidinedioneModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Pioglitazone et glimépiridethiazolidinedioneModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Pioglitazone et metforminethiazolidinedioneModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Pitolisantmédicament allongeant l'intervalle QTModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Posaconazoleantifongique azoléModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • PrazosinealphabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • PrimidoneanticonvulsivantModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • ProcaïnamideantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • ProméthazineantihistaminiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Prométhazine et codéineopioïdeModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Prométhazine et dextrométhorphaneantihistaminiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • PropafénoneantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • PropranololbêtabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • PropylthiouracileantithyroïdienModérée

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (notice Sunitinib, Mises en garde et précautions)

  • QuétiapineantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Quinaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • QuinidineantiarythmiqueModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • QuinineantipaludiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Ramiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Ranolazinemédicament allongeant l'intervalle QTModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • RépaglinideglinideModérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • RifabutineantibiotiqueModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • RifampicineantibiotiqueModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • RifapentineantibiotiqueModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • RispéridoneantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • RitonavirantirétroviralModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Sacubitril et valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Saxagliptineinhibiteur de la DPP-4Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Saxagliptine et metformineinhibiteur de la DPP-4Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Sémaglutideagoniste du récepteur du GLP-1Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Sitagliptineinhibiteur de la DPP-4Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • Sitagliptine et metformineinhibiteur de la DPP-4Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • SolifénacineanticholinergiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • SotalolbêtabloquantModérée

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (notice Sunitinib, Mises en garde et précautions)

  • Spironolactoneantagoniste de l'aldostéroneModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Suvorexantsédatif-hypnotiqueModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Suzétrigineinducteur du CYP3A4Modérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • TacrolimusimmunosuppresseurModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Tamoxifènemodulateur sélectif des récepteurs aux estrogènesModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Telmisartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Telmisartan et amlodipineantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • TemsirolimusModérée

    Concomitant use of TORISEL with sunitinib The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. (notice Temsirolimus, Mises en garde et précautions)

  • TérazosinealphabloquantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Tériparatidehormone thyroïdienneModérée

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (notice Sunitinib, Mises en garde et précautions)

  • Tétrabénazineinhibiteur de VMAT2Modérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • ThiamazoleantithyroïdienModérée

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (notice Sunitinib, Mises en garde et précautions)

  • ThioridazineantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Ticagrélorantiagrégant plaquettaireModérée

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (notice Sunitinib, Mises en garde et précautions)

  • Tirzépatideagoniste du récepteur du GLP-1Modérée

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (notice Sunitinib, Mises en garde et précautions)

  • TizanidinemyorelaxantModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • ToltérodineanticholinergiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • TopiramateanticonvulsivantModérée

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (notice Sunitinib, Interactions médicamenteuses)

  • Torasémidediurétique de l'anseModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Torémifènemodulateur sélectif des récepteurs aux estrogènesModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • TramadolopioïdeModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Tramadol et paracétamolopioïdeModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Trandolaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • TrazodoneantidépresseurModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Triamtérènediurétique épargneur de potassiumModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Trioxyde d'arsenicmédicament allongeant l'intervalle QTModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Valbénazineinhibiteur de VMAT2Modérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • Vardénafilinhibiteur de la PDE5Modérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • VenlafaxineIRSNaModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

  • Vérapamilinhibiteur calciqueModérée

    Initiate and/or adjust antihypertensive therapy as appropriate. (notice Sunitinib, Mises en garde et précautions)

  • ZiprasidoneantipsychotiqueModérée

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (notice Sunitinib, Interactions médicamenteuses)

Mentions mineures (1)

  • AxitinibMineure

    MACE occurred in 7% of patients with advanced RCC treated with INLYTA in combination with avelumab compared to 3.4% treated with sunitinib in a randomized trial, JAVELIN Renal 101. (notice Axitinib, Mises en garde et précautions)

Vérifiez Sunitinib avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.